Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its ...

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

Gastroesophageal Junction (GEJ): The area where the esophagus meets the stomach, which can be affected by specific types of cancer. This Nature Research Intelligence Topic summary is one of 30,000 ...

Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...

Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction ...

Conversion therapy has become a hot topic among specialists in gastrointestinal cancers, said Pamela Kunz, MD, of the Yale ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

In gastric cancer, Keytruda is approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic ...